(prw) -- Bayer has reported solid Q2 revenues but recorded a 1.3% slip in earnings due to one-off charges for legal proceedings and a write-down on a cancer drug.
Revenues rose 14.6% to ┬9.2bn, up from ┬8bn, due largely to growth in its consumer health and high-tech materials divisions. But total earnings of ┬525m in the April to June period were down from ┬532m for the same period the previous year as a result of the one-off hits.
MRCMRC Reference
Bayer is an international chemical and pharmaceutical concern. Founded in 1863.
The share in the Russian market in 2008:
PS - 0.7% (ABS - 7.2%).
Annual sales growth in Russia over the last 5 years:
PS - (-10%).
Polymers processing technologies:
injection molding.